NINLARO: payments to doctors
Payments that named NINLARO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $5.9M
- Providers
- 7,929
- Transactions
- 23,798
- Average per transaction
- $247
The per-transaction average — $247 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 7,929 providers the average total is $741, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $5,871,177 | 99.9% |
| Takeda Pharmaceutical Company, Limited | $6,400 | 0.1% |